Citius Oncology, Inc. Operating Income
Citius Oncology, Inc. (CTOR) reported Operating Income of -$8.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-14
- Citius Oncology, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$8.72M.
- Citius Oncology, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$28.61M.
- Citius Oncology, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$5.25M.
- Citius Oncology, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$4.71M.
- Citius Oncology, Inc. operating income (loss) for fiscal 2025 was -$23.52M.
- Citius Oncology, Inc. operating income (loss) for fiscal 2024 was -$20.57M.
- Citius Oncology, Inc. operating income (loss) for fiscal 2023 was -$1.01M.
- Citius Oncology, Inc. operating income (loss) for fiscal 2022 was -$138.12K.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 10 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.72M 10-Q · filed 2026-08-14 | -$37.33M derived: sum of 2 quarters · filed 2026-08-14 | -$42.58M 10-Q · filed 2026-08-14 | -$47.29M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | -$28.61M 10-Q · filed 2026-05-15 | -$33.87M 10-Q · filed 2026-05-15 | -$38.58M derived: sum of 3 quarters · filed 2026-05-15 | -$43.52M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | -$5.25M 10-Q · filed 2026-02-13 | -$9.96M derived: sum of 2 quarters · filed 2026-02-13 | -$14.91M derived: sum of 3 quarters · filed 2026-08-14 | -$22.38M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-09-30 | -$4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | -$9.66M derived: sum of 2 quarters · filed 2026-08-14 | -$17.13M derived: sum of 3 quarters · filed 2026-08-14 | -$23.52M 10-K · filed 2025-12-23 | ||
| 2025-06-30 | -$4.94M 10-Q · filed 2026-08-14 | -$12.42M derived: sum of 2 quarters · filed 2026-08-14 | -$18.81M 10-Q · filed 2026-08-14 | -$25.48M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | -$7.47M 10-Q · filed 2026-05-15 | -$13.87M 10-Q · filed 2026-05-15 | -$20.54M derived: sum of 3 quarters · filed 2026-05-15 | -$25.16M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | -$6.39M 10-Q · filed 2026-02-13 | -$13.06M derived: sum of 2 quarters · filed 2026-02-13 | -$17.69M derived: sum of 3 quarters · filed 2026-02-13 | -$17.96M derived: sum of 4 quarters · filed 2026-02-13 | ||
| 2024-09-30 | -$6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | -$11.30M derived: sum of 2 quarters · filed 2025-12-23 | -$11.57M derived: sum of 3 quarters · filed 2025-12-23 | -$20.57M 10-K · filed 2025-12-23 | ||
| 2024-06-30 | -$4.63M 10-Q · filed 2025-08-12 | -$383.96K 10-Q · filed 2024-08-09 | -$652.39K 10-Q · filed 2024-08-09 | -$13.90M 10-Q · filed 2025-08-12 | -$5.56M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$268.43K 10-Q · filed 2024-05-20 | -$512.57K derived: sum of 2 quarters · filed 2024-05-20 | -$934.02K derived: sum of 3 quarters · filed 2024-05-20 | -$1.13M derived: sum of 4 quarters · filed 2024-08-09 | ||
| 2023-12-31 | -$244.14K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$665.59K derived: sum of 2 quarters · filed 2024-04-16 | -$865.15K derived: sum of 3 quarters · filed 2024-08-09 | -$1.01M 10-K · filed 2024-04-16 | ||
| 2023-09-30 | -$421.45K 10-Q · filed 2023-11-20 | -$621.01K derived: sum of 2 quarters · filed 2024-08-09 | -$768.93K 10-Q · filed 2023-11-20 | |||
| 2023-06-30 | -$199.55K 10-Q · filed 2024-08-09 | -$347.48K 10-Q · filed 2024-08-09 | ||||
| 2023-03-31 | -$147.92K 10-Q · filed 2024-05-20 | |||||
| 2022-12-31 | -$138.12K 10-K · filed 2024-04-16 | |||||
| 2021-12-31 | -$10.11K 10-K · filed 2023-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |